These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6832880)

  • 21. Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy.
    Hong Kong Chest Service/British Medical Research Council
    Am Rev Respir Dis; 1989 Dec; 140(6):1618-22. PubMed ID: 2604291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
    Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
    Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis.
    Am Rev Respir Dis; 1979 Apr; 119(4):579-85. PubMed ID: 375787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
    Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
    Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of various drug regimens in domiciliary chemotherapy.
    Mehrotra ML; Pande DC; Grover KL; Gautam KD
    Am Rev Respir Dis; 1970 Oct; 102(4):607-13. PubMed ID: 4195520
    [No Abstract]   [Full Text] [Related]  

  • 26. Any questions? How should a patient be managed who is being treated for sputum positive pulmonary tuberculosis and becomes jaundiced in the third week of chemotherapy?
    Campbell IA
    Tubercle; 1990 Jun; 71(2):149. PubMed ID: 2219468
    [No Abstract]   [Full Text] [Related]  

  • 27. Isoniazid induced gynaecomastia: a case report.
    Garg R; Vaibhav ; Mehra S; Prasad R
    Indian J Tuberc; 2009 Jan; 56(1):51-4. PubMed ID: 19402273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pyrazinamide-induced granulomatous hepatitis.
    Knobel B; Buyanowsky G; Dan M; Zaidel L
    J Clin Gastroenterol; 1997 Jun; 24(4):264-6. PubMed ID: 9252856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
    Su WJ; Perng RP
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):1029-32. PubMed ID: 12475151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The effectiveness of pyrazinamide-containing six-month short course chemotherapy].
    Wada M
    Kekkaku; 2000 Nov; 75(11):665-73. PubMed ID: 11140090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pellagra encephalopathy among tuberculous patients: its relation to isoniazid therapy.
    Ishii N; Nishihara Y
    J Neurol Neurosurg Psychiatry; 1985 Jul; 48(7):628-34. PubMed ID: 4031907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New and future drugs in pulmonary tuberculosis].
    Grosset JH; Truffot-Pernot C; Lecoeur H
    Prax Klin Pneumol; 1988 Jun; 42 Suppl 1():206-10. PubMed ID: 3174565
    [No Abstract]   [Full Text] [Related]  

  • 33. Isoniazid induced pellagra despite pyridoxine supplementation.
    Darvay A; Basarab T; McGregor JM; Russell-Jones R
    Clin Exp Dermatol; 1999 May; 24(3):167-9. PubMed ID: 10354170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
    Schechter M; Zajdenverg R; Falco G; Barnes GL; Faulhaber JC; Coberly JS; Moore RD; Chaisson RE
    Am J Respir Crit Care Med; 2006 Apr; 173(8):922-6. PubMed ID: 16474028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Controlled clinical study on efficacy of fixed-dose compounds rifater/rifinah in antituberculous chemotherapy].
    Zhu L; Yan B; Ma W
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Nov; 21(11):645-7. PubMed ID: 11477887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Case of fatal liver failure due to anti-tuberculous therapy].
    Harada Y; Kawakami K; Koyama K; Yamaryo T; Kimura Y
    Kekkaku; 2007 Sep; 82(9):705-9. PubMed ID: 17969987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Fully supervised ambulatory short-course chemotherapy with an intermittent regimen for newly diagnosed smear-positive pulmonary tuberculosis].
    Xu RX
    Zhonghua Jie He He Hu Xi Za Zhi; 1987 Oct; 10(5):261-3, 307. PubMed ID: 3131029
    [No Abstract]   [Full Text] [Related]  

  • 38. Unilateral and painless development of isoniazid induced gynecomastia during re-treatment of pulmonary tuberculosis.
    Kumar L; Gupta R; Puri MM; Jaiswal A; Srinath ; Murar A; Behera D
    J Assoc Physicians India; 2011 Nov; 59():733-5. PubMed ID: 22616343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Short-course chemotherapy of tuberculosis with pyrazinamide].
    Asai S; Futsuki Y; Tomari S; Araki J
    Nihon Rinsho; 1998 Dec; 56(12):3087-90. PubMed ID: 9883615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.
    Stout JE
    Expert Opin Drug Saf; 2004 May; 3(3):187-98. PubMed ID: 15155147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.